Skip to main content

Table 10 (abstract P455). Patients characteristics at study treatment onset

From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part three

 

Ada (n = 16)

Placebo (n = 15)

All (n = 31)

Female, n (%)

15 (94)

13 (87)

28 (90)

Age, median value, years [ranges

10.8 [5.0-20.3]

9.2 [4.9-29.1]

 

Active joints, median n [ranges]

0 [0-3]

0 [0-4]

0 [0-4]

Uveitis median duration, years [ranges]

4.4 [0.4-18.9]

4.8 [0.6-24.2]

 

Laser flare (ph/ms), median [ranges]

99 [23-322]

70 [36-265]

 

Bilateral uveitis, n (%)

10 (63)

14 (93)

24 (78)

Ongoing treatments at D1

 Oral steroids, patients n (%)

7 (44)

3 (20)

10 (32)

 Methotrexate, patients n (%)

15 (94)

11 (73)

26 (84)

  1. At M2, in intention-to-treat (1ary objective), there were 9/16 responders in the adalimumab group and 3/15 in the placebo group (p = 0.038, Chi-squared test; RR = 2.81, CI95% = [0.94-8.45] with log-binomial model estimation). Among responders to adalimumab, patients with very high laser flare photometry values showed quick improvement. One patient stopped the trial at D14 (adalimumab group, uveitis worsening) and one at M9 (ocular hypertony). 29 patients reached M12 on adalimumab. There were 6 serious adverse events in 5 patients, all in the placebo group, 5 during the open-label phase, none related to study treatment (investigator assessment)
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096